Genetically Engineered Yeast for Sphingoid Base Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing sphingosine and sphingosine-containing sphingolipids are costly and inefficient, with chemical synthesis resulting in racemic mixtures and natural sources being expensive and potentially unsafe due to compositional heterogeneity and pathogenic risks.
Innovation Solution
Genetically engineered yeast strains with modified expression and enzyme activity levels of ceramide synthase, dihydroceramide desaturase, and ceramidase are developed to increase production of sphingoid bases like sphingosine, enabling the efficient production of complex sphingolipids such as ceramides, cerebrosides, and gangliosides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If chemical synthesis is used to produce sphingosine, then production cost is reduced, but the product becomes a racemic mixture with only 25% representing the naturally occurring configuration
Solution Approach 1:
The patent replaces chemical synthesis methods with biological synthesis using genetically engineered microorganisms. The microbial cell machinery (enzymes, metabolic pathways) naturally produces only the desired D-erythro-(2R,3S)-configuration sphingosine, eliminating the need for complex chiral resolution processes while maintaining low production costs.
Solution Approach 2:
The patent modifies the genetic parameters of microorganisms by introducing and overexpressing specific genes (e.g., SUR2, LAG1, LAF1, DES1) to optimize the metabolic pathway for sphingosine production. This genetic engineering approach changes the biological parameters of the production system to achieve both cost-effectiveness and high stereoisomer purity.
2Manufacturing precision
If pure sphingosine is isolated from natural sources, then high purity is achieved, but the cost becomes extremely high
Solution Approach 1:
The patent employs microorganisms that naturally produce sphingosine as part of their metabolic processes. By genetically engineering these organisms to overproduce sphingosine, the system essentially serves itself, accumulating the desired compound through natural biological functions rather than requiring expensive extraction and purification from natural sources.
Solution Approach 2:
The patent extracts the essential production capability from complex natural sources and transfers it to genetically engineered microorganisms. By isolating and overexpressing specific genes responsible for sphingosine biosynthesis, the system captures the valuable production function while eliminating the need to process expensive natural materials like brain or chicken eggs.
3Ease of manufacture
If heterogeneous sphingolipid preparations are extracted from animal sources, then cost is reduced, but safety and compositional homogeneity deteriorate
Solution Approach 1:
The patent replaces animal source extraction with microbial fermentation. The genetically engineered microorganisms produce sphingosine and sphingolipids through controlled metabolic pathways, eliminating concerns about pathogenic agents while maintaining cost-effectiveness. The microbial production system provides inherent biosafety and compositional consistency.
Solution Approach 2:
The patent changes the production system from heterogeneous animal-derived materials to homogeneous microbial biomass. By controlling the genetic makeup and metabolic conditions of the microorganisms, the system achieves consistent, reproducible production of defined sphingolipid compositions without the variability and safety risks associated with animal source materials.
4Productivity
If existing yeast strains are used for sphingoid base production, then production is achieved, but the amount of desired sphingoid bases remains very low
Solution Approach 1:
The patent performs preliminary genetic engineering of yeast strains by introducing and overexpressing specific genes (SUR2, LAG1, LAF1, DES1) before production. This preliminary modification of the metabolic pathway prepares the organism to efficiently channel resources toward sphingosine production, dramatically increasing yield without complicating the overall production process.
Solution Approach 2:
The patent uses Saccharomyces cerevisiae, a universally applicable yeast platform that can be genetically modified and cultured under standard conditions. The engineered strain maintains the versatility of standard yeast cultivation while gaining enhanced sphingosine production capability, combining process simplicity with high productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The genetically engineered yeast strains produce significant amounts of sphingoid bases, overcoming the limitations of chemical synthesis and natural source extraction, providing a cost-effective and safe method for sphingolipid production.
Implementation Method 1
Genetically engineered yeast strains with modified expression and enzyme activity levels of ceramide synthase, dihydroceramide desaturase, and ceramidase are developed to increase production of sphingoid bases like sphingosine
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The present invention provides genetically engineered microbial strains, in particular genetically engineered yeast strains, that produce at least 0.5 mg per g CDW of a sphingoid base according to Formula I or a salt or ester thereof. The present invention provides a method to obtain genetically engineered microbial strains producing at least 0.5 mg per g CDW of a sphingoid base according to Formula I or a salt or ester thereof. The method comprises the steps of: a) increasing the expression of a polynucleotide encoding an enzyme having ceramide synthase activity and/or an enzyme having ceramidase activity, the latter being capable of preferentially, or even specifically, hydrolyzing ceramides containing a sphingoid base according to Formula I, and/or b) decreasing the expression of a polynucleotide encoding an enzyme having sphingolipid ?8-desaturase activity and/or an enzyme having ceramidase activity, the latter being capable of preferentially, or even specifically, hydrolyzing ceramides containing phytosphingosine or dihydrosphingosine as sphingoid base, and isolating strains with the required productivity.